Abstract
Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?
This is a preview of subscription content, log in via an institution to check access.
Acknowledgements
The author would like to acknowledge the members of Ortho Biotech Oncology Research and Development who helped formulate the concepts contained herein, and those who reviewed the manuscript and offered helpful comments.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hait, W. Anticancer drug development: the grand challenges. Nat Rev Drug Discov 9, 253–254 (2010). https://doi.org/10.1038/nrd3144
Issue Date:
DOI: https://doi.org/10.1038/nrd3144
- Springer Nature Limited
This article is cited by
-
Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
Microbial Cell Factories (2023)
-
Synthesis and biological screening of a novel enaminone-grafted trithiocarbonate: a potential anticancer and antimicrobial agent
Medicinal Chemistry Research (2020)
-
Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts
Breast Cancer Research and Treatment (2019)
-
Novel 3D Liquid Cell Culture Method for Anchorage-independent Cell Growth, Cell Imaging and Automated Drug Screening
Scientific Reports (2018)
-
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Nature Reviews Drug Discovery (2018)